Van ECK Associates Corp lessened its stake in Insulet Co. (NASDAQ:PODD – Free Report) by 2.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission.

Insulet (PODD) has disclosed a new risk, in the Natural and Human Disruptions category. Insulet faces significant business and financial risks ...

Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...

Shares of Insulet Corp. PODD slid 1.90% to $282.80 Friday, on what proved to be an all-around dismal trading session for the ...

Insulet's Q4 sales grew 17.2% to $597.5 million, exceeding forecasts. Omnipod revenue surged, and 2025 guidance projects up to 20% growth.

Raymond James analyst Jayson Bedford raised the firm’s price target on Insulet (PODD) to $328 from $294 and keeps an Outperform rating on the ...

Stifel Nicolaus analyst Mathew Blackman maintained a Hold rating on Insulet (PODD – Research Report) today and set a price target of $293.00.

CIBC Asset Management Inc increased its position in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 4.7% in the 4th ...

Insulet forecasts total company revenue growth of 16%-20% for 2025, with Omnipod revenue growth projected at 17%-21%. U.S. Omnipod revenue is expected to grow 16%-20%, driven by the continued ramp-up ...

Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...